Max Nisen, Columnist

Allergan Guilty of Wishful Botox Thinking

Pushing iffy Phase 2 trial data into Phase 3 is a common recipe for failure.

April 6, 2017 at 5:35 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

Analyze any failure long enough and you might find a success.

Allergan PLC Wednesday night reported data from a mid-stage trial of Botox in treating major depressive disorder and announced it planned to run a bigger trial for the drug. The rather significant wrinkle is that the drug didn't clearly succeed in the smaller trial.